Loading...
•
Jun 30, 2022
Maravai Q2 2022 Earnings Report
Reported record first half revenue, net income, adjusted EBITDA and EPS.
Key Takeaways
Maravai LifeSciences reported a solid quarter with total revenues reaching $242.7 million, up 11% over the second quarter of 2021. The results include 27% revenue growth in the Nucleic Acid Production base business, after excluding the effect of an estimated $178 million of COVID-19-related CleanCap revenue in the quarter. Net income was $156.7 million for the second quarter, representing growth of 17% over the prior year.
Quarterly revenue of $242.7 million, an increase of 11% over the prior year.
Nucleic Acid Production base business revenue (excluding estimated COVID-19 related CleanCap® revenue) increased 27% over the prior year.
Net income of $156.7 million for the second quarter, representing growth of 17% over the prior year.
Record Adjusted EBITDA margins of 78%.
Revenue by Segment
Forward Guidance
Total revenue for 2022 is projected to be in the range of $880.0 million to $910.0 million, reflecting overall growth of 10% to 14%. Adjusted EBITDA (non-GAAP) is now expected to be in the range of $640.0 million to $660.0 million. Adjusted fully diluted EPS (non-GAAP) is now expected to be in the range of $1.70 - $1.80 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...